Blood Test for detecting Colorectal Cancers

Blood Test for detecting Colorectal Cancers

Colorectal cancer (CRC) is the second most common internal cancer in Australia in men and women. Age, family history, shift work and lifestyle choices all impact on colorectal cancer risk. Australia (together with New Zealand) has one of the highest incidence rates of colorectal cancer globally.

Doctors currently use diagnostic tests such as colonoscopies and histological analysis of biopsy samples to detect the presence and assess the stage of colorectal cancers. The current laboratory-screening test predominantly used for detection of colorectal cancer is the Faecal Occult Blood Test (FOBT), or more specifically now the Faecal Immunochemical Test (FIT or iFOBT).

Previous studies have identified specific biomarkers in blood which can be used to derive a colorectal cancer risk score. These protein biomarkers form the basis for the proposed ColoSTAT technology. This study intends to determine the performance of ColoSTAT in detecting colorectal cancers compared with the gold standard - colonoscopy.

Who can participate?

You may be eligible for this study if you:

  • Are between 40 to 75 years of age
  • Have no prior history of colorectal cancer and are scheduled to undergo a colonoscopy in the next 90 days OR
  • Diagnosed with colorectal cancer and progressing to surgery, chemo or radiation therapy in the next 30days.

Study Details:

If you are eligible to be involved in the study, you will be asked to attend the clinic once and attend for the scheduled colonoscopy or surgery. There will also be a follow up phone call after the colonoscopy or surgery procedure.


Study Locations:

This study is currently looking for participants in NSW, VIC, QLD and WA.

If you would like to learn more, please click here and one of our clinical trials team member will contact you.